CM
PTCT icon

CM Management’s PTC Therapeutics PTCT Stock Holding History

CM Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-45,000
Closed -$1.8M – 74
2022
Q2 		$1.8M Buy
45,000
+5,000
+13% +$175K 1.92% 15
2022
Q1 		$1.49M Buy
40,000
+5,000
+14% +$193K 1.25% 28
2021
Q4 		$1.39M Buy
35,000
+5,000
+17% +$191K 1.05% 30
2021
Q3 		$1.12M Hold
30,000
– – 0.83% 42
2021
Q2 		$1.27M Buy
30,000
+5,000
+20% +$214K 0.92% 41
2021
Q1 		$1.18M Hold
25,000
– – 0.88% 44
2020
Q4 		$1.53M Buy
+25,000
New +$1.47M 1.42% 24

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

CM Management's PTCT Position: Q3 2022 in Review

CM Management sold out of PTC Therapeutics (PTCT) in Q3 2022, closing a stake of 45,000 shares — an estimated $1.8M sold.

CM Management first reported a position in PTCT in Q4 2020 and held it in 7 quarters. The position peaked at $1.8M in Q2 2022. 213 funds tracked by Wall St. Rank hold PTCT as of Q3 2022.

  • CM Management reported no remaining PTC Therapeutics position as of Q3 2022 after selling out during the quarter.
  • CM Management sold 45,000 PTC Therapeutics shares in Q3 2022, an estimated $1.8M.
  • CM Management first reported a position in PTC Therapeutics in Q4 2020 and held it in 7 quarters.
  • CM Management's PTC Therapeutics position peaked at $1.8M in Q2 2022.
  • 213 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2022.

Based on CM Management's 13F filing for Q3 2022, filed 4 Nov 2022.